Dasatinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dasatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dasatinib overview
Dasatinib (Sprycel) is an anti-neoplastic agent. It is formulated as tablets, film coated tablets, coated tablets and powder for suspension for oral administration. It is indicated for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib in adults and also for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy in adults. Sprycel is also indicated for the treatment of adults and pediatrics with newly diagnosed Philadelphia chromosome – positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, and also indicated for the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.
Dasatinib is under development for the treatment of inflammation caused by Coronavirus disease 2019 (COVID-19), non-small cell lung cancer, breast cancer (adjuvant), chronic myelocytic leukemia (1L, 2L) and acute lymphocytic leukemia (2L). It is administered by oral route. The drug candidate was also under development for the treatment of estrogen/progesterone receptor-positive or Her2/Neu-positive breast cancer, pancreatic cancer, relapsed or refractory diffuse large B-cell lymphoma, scleroderma pulmonary interstitial fibrosis, relapsed multiple myeloma, agnogenic myeloid metaplasia – myelofibrosis, hypereosinophilic syndrome, acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, systemic mastocytosis, oligodendroglioma, peripheral T-cell lymphoma, refractory multiple myeloma, melanoma, intrahepatic cholangiocarcinoma, metastatic breast cancer, HER2 negative breast cancer, recurrent glioblastoma, gliosarcoma, pulmonary arterial hypertension and non-Hodgkin lymphoma including Mantle cell lymphoma, diffuse large B cell lymphoma, natural killer cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoblastic lymphoma and HIV infection. It was under development for the treatment of triple-negative breast cancer.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
For a complete picture of Dasatinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
